<DOC>
	<DOCNO>NCT00000989</DOCNO>
	<brief_summary>AMENDED : To evaluate effect sargramostim ( GM-CSF ) modulate granulocytopenia associate concomitant DHPG AZT therapy ( Phase B ) , term time development granulocytopenia define absolute neutrophil count ( ANC ) less equal 750 cells/mm3 . Original design : To determine granulocyte-macrophage colony-stimulating factor ( GM-CSF ) helpful prevent decreased number white blood cell ( infection-fighting cell ) associate ganciclovir ( DHPG ) therapy determine GM-CSF safely use AIDS patient cytomegalovirus ( CMV ) retinitis . AMENDED : In ACTG 004 , among 11 AIDS patient CMV infection receive DHPG maintenance therapy ( 5 mg/kg , 5x/week ) stable white blood cell ( WBC ) /absolute neutrophil count ( ANC ) 7 ( 64 percent ) require dose reduction discontinuation antiviral medication due granulocytopenia AZT ( 600 mg/day ) add . A mean nadir ANC 717 cells/ml reach mean 5 week concomitant DHPG/AZT therapy patient . While recovery depress ANC occur follow discontinuation study medication , progressive CMV infection ( commonly retinitis ) occur 19 40 patient seem associated DHPG therapy interruption . Only 3 40 patient able tolerate complete 16 week study duration DHPG/AZT . Pharmacokinetic study co-administration DHPG AZT reveal significant drug-drug interaction . The study investigator conclude main , treatment limit toxicity combination DHPG/AZT therapy granulocytopenia many patient treat study develop intercurrent OIs staphylococcal septicemia . In order determine whether patient receive maintenance DHPG therapy without GM-CSF tolerate concomitant AZT therapy , extend maintenance therapy assign study regimen combination AZT incorporate protocol . Original design : CMV infection cause inflammation retina lead permanent blindness . Treatment CMV retinitis DHPG show effective halting progression retinal disease . During DHPG treatment , however , 30 55 percent patient develop decreased white blood cell count . GM-CSF , naturally occur human hormone , stimulate body 's bone marrow produce white blood cell . Studies GM-CSF AIDS patient show significantly increase depressed white blood cell count patient .</brief_summary>
	<brief_title>The Safety Effectiveness Ganciclovir Used Alone Combination With Granulocyte-Macrophage Colony Stimulating Factor Treatment Cytomegalovirus ( CMV ) Eye Patients With AIDS</brief_title>
	<detailed_description>AMENDED : In ACTG 004 , among 11 AIDS patient CMV infection receive DHPG maintenance therapy ( 5 mg/kg , 5x/week ) stable white blood cell ( WBC ) /absolute neutrophil count ( ANC ) 7 ( 64 percent ) require dose reduction discontinuation antiviral medication due granulocytopenia AZT ( 600 mg/day ) add . A mean nadir ANC 717 cells/ml reach mean 5 week concomitant DHPG/AZT therapy patient . While recovery depress ANC occur follow discontinuation study medication , progressive CMV infection ( commonly retinitis ) occur 19 40 patient seem associated DHPG therapy interruption . Only 3 40 patient able tolerate complete 16 week study duration DHPG/AZT . Pharmacokinetic study co-administration DHPG AZT reveal significant drug-drug interaction . The study investigator conclude main , treatment limit toxicity combination DHPG/AZT therapy granulocytopenia many patient treat study develop intercurrent OIs staphylococcal septicemia . In order determine whether patient receive maintenance DHPG therapy without GM-CSF tolerate concomitant AZT therapy , extend maintenance therapy assign study regimen combination AZT incorporate protocol . Original design : CMV infection cause inflammation retina lead permanent blindness . Treatment CMV retinitis DHPG show effective halting progression retinal disease . During DHPG treatment , however , 30 55 percent patient develop decreased white blood cell count . GM-CSF , naturally occur human hormone , stimulate body 's bone marrow produce white blood cell . Studies GM-CSF AIDS patient show significantly increase depressed white blood cell count patient . AMENDED : Following completion Phase A , study participant may elect extend assign maintenance therapy ( DHPG alone DHPG/GM-CSF ) combination AZT therapy ( Phase B ) . GM-CSF dosing titrate maintain target ANC 2500-5000 cells/mm3 . Those patient receive DHPG/AZT develop neutropenia ( ANC le 750/ml ) two occasion begin GM-CSF maintain target ANC 2500-5000 cells/mm3 . A similar schedule clinical , ophthalmologic laboratory evaluation follow order determine efficacy safety extend maintenance therapy combine AZT . Close monitor antiviral ( CMV , HIV ) immunomodulatory activity assess . This second phase study last additional 52 week . AMENDED : Extended 68 week . Original design : Patients hospitalize minimum 7 day begin treatment CMV retinitis . They randomly assign one two group receive DHPG either without GM-CSF . DHPG give intravenous infusion every 12 hour first 14 day . DHPG maintenance therapy give day , 7 days/week remain 14 week study . For patient DHPG GM-CSF group , GM-CSF give subcutaneous injection 16 week study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Maintenance therapy stable opportunistic infection myelosuppressive . Aerosolized pentamidine prophylaxis Pneumocystis carinii pneumonia . Acyclovir appropriate medication appearance Herpes simplex virus Varicella zoster virus infection ( enrollment study ) require systemic therapy . Medications absolutely necessary patient 's welfare , discretion investigator . Patients must : Have diagnosis sightthreatening cytomegalovirus ( CMV ) retinitis AIDS . Have least one pending culture cytomegalovirus ( CMV ) buffy coat and/or urine prior study entry previously document CMV viremia viruria within 6 week prior study entry . Be capable give informed consent . Exclusion Criteria Coexisting Condition : Patients follow exclude : Corneal , lenticular , vitreal opacification precludes examination fundus , evidence retinopathy cotton wool spot . Concurrent Medication : Excluded : Systemic antiviral therapy except Zidovudine ( AZT ) add extended maintenance phase study . Foscarnet . Treatment active AIDSdefining opportunistic infection . Any potentially cytotoxic chemotherapeutic agent . Patients follow exclude : Corneal , lenticular , vitreal opacification precludes examination fundus , evidence retinopathy cotton wool spot . Prior Medication : Excluded within 14 day study entry : Other immunomodulators , biologic response modifier , investigational agent . Protocol drug . Foscarnet . Any potentially cytotoxic chemotherapeutic agent . Prior Treatment : Excluded within 14 day study entry : Administration cytomegalovirus hyperimmune globulin therapeutic dos .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>